Partial thickness sclerectomy and intravitreal anti-VEGF therapy for intractable uveal effusion syndrome

Int Ophthalmol. 2019 Aug;39(8):1885-1890. doi: 10.1007/s10792-018-0992-1. Epub 2018 Jul 24.

Abstract

Purpose: To report a case series of three patients with intractable uveal effusion syndrome (UES), treated with partial thickness sclerectomy and intravitreal anti-VEGF therapy.

Methods: Three patients with intractable UES were included. All patients underwent intravitreal anti-VEGF therapy to facilitate resolution of uveal effusion. The concentrations of IL-1β, IL-6, IL-8, IL-10, IL-12p70, TNF and VEGF in aqueous humor were measured.

Results: After the last intravitreal injection, all three eyes had total resolution of the chorioretinal detachment or subretinal fluid. One eye experienced improvement in visual acuity. All patients were free from recurrence during the follow-up period. Aqueous IL-6, IL-8 and VEGF concentrations were elevated in all cases.

Conclusions: Our current data provided the evidence that VEGF was increased in eyes with intractable UES and anti-VEGF therapy was effective, suggesting that partial thickness sclerectomy and intravitreal anti-VEGF therapy could be a new choice for intractable UES.

Keywords: Aqueous VEGF concentration; Intractable uveal effusion syndrome; Intravitreal anti-VEGF therapy.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Angiogenesis Inhibitors / administration & dosage
  • Aqueous Humor / metabolism
  • Bevacizumab / administration & dosage*
  • Cytokines / metabolism
  • Exudates and Transudates
  • Female
  • Fluorescein Angiography / methods
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Intravitreal Injections
  • Male
  • Microscopy, Acoustic
  • Middle Aged
  • Ophthalmologic Surgical Procedures / methods*
  • Ranibizumab / administration & dosage*
  • Retina / pathology*
  • Retinal Detachment / complications
  • Retinal Detachment / diagnosis
  • Retinal Detachment / therapy*
  • Retrospective Studies
  • Sclera / surgery*
  • Syndrome
  • Uveal Diseases / complications
  • Uveal Diseases / diagnosis
  • Uveal Diseases / therapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity

Substances

  • Angiogenesis Inhibitors
  • Cytokines
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Ranibizumab